Company intelligence
Medicines for Malaria Venture
Ending malaria, rewriting the future
About Medicines for Malaria Venture
MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease. Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries. www.mmv.org www.facebook.com/medicinesformalaria www.twitter.com/medsformalaria www.youtube.com/user/MMVmeds4malaria http://plus.google.com/+mmvorgmedsformalaria
Verified activity
Signals from Medicines for Malaria Venture
5 published signals
Presence & Recognition
Medicines for Malaria Venture expressed profound sadness at the news of Vasee Moorthy's untimely passing.
Reported by Medicines for Malaria Venture
Research & Knowledge
Medicines for Malaria Venture published its latest monthly newsletter celebrating Geneva's role as a meeting point for global health and partnerships charting a path towards malaria elimination.
Reported by Medicines for Malaria Venture
Partnerships
Medicines for Malaria Venture is seeking qualified organizations based in or operating in malaria-endemic countries to join a network of potential partners with expertise in market research, secondary data access and analysis, health economics and outcomes research, cost-effectiveness and value assessment, and social science research.
Reported by Medicines for Malaria Venture
Partnerships
Medicines for Malaria Venture launched WANECAM3, a collaboration bringing together 11 partners across Africa and Europe to advance next-generation antimalarial drug treatments through Phase 2 and Phase 3 clinical trials.
Reported by Medicines for Malaria Venture
Research & Knowledge
Medicines for Malaria Venture scientists in Tanzania found evidence that a marker of partial artemisinin resistance is expanding geographically in the Kagera region through molecular surveillance.
Reported by Medicines for Malaria Venture